| |
Dear Colleague,
To address the unmet needs of ocular disease drug therapies and the growing population of aging individuals, GTCbio is proud to announce its 2nd Annual Ocular Diseases & Drug Discovery conference, taking place on May 27-28, 2010 in Boston, MA.
In 2005, the National Eye Institute (NEI) estimated that the annual cost of vision impairment and eye disease to the United States was $68 billion. Not only are eye diseases costly to the US, they also impact the quality of life of over 34 million people, causing lost productivity, reduced independence, diminished quality of life, increased depression and accelerated mortality. By 2020, this number is expected to grow to over 50 million.
Several companies have taken the initiative in developing ocular disease therapies, including companies such as Pfizer, EyeGate, pSivida, Merck, Regeneron, Genzyme, Novartis, Ophthotech, Macusight, Neurotech, GlaxoSmithKline and many more. To help promote the discovery of ocular disease and drug development, GTCbio is bringing together leading scientists, researchers, and experts to discuss and collaborate on the latest research & drugs available in combating and curing age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, uveitis and other eye diseases at the Ocular Diseases & Drug Discovery conference.
The conference features the following sessions:
Session I: Age-Related Macular Degeneration
Session II: Ocular Diseases
Session III: Recent Drug Developments & Mechanisms in Ocular Diseases
Session IV: Future of Ocular Diseases Therapeutics
Session V: Novel Drug Delivery Methods
Best regards,
2010 Conference Advisory Committee
 |
Attend ONE additional Conference of your choice for only $400 more. Click here to sign up! |
| |
|
 |
Attend ALL 2010 GTCbio Conferences for only $3000 ($1595 for academia). Click here to sign up! |
| |
|
|
Media Partners:
|
|
|
|
|
|
| |
| |
|
|
|
|